Skip to main content
Erschienen in: European Journal of Pediatrics 4/2024

01.02.2024 | RESEARCH

Clinical characteristics and risk factors of cardiac involvement in pediatric immunoglobulin A vasculitis: A 7-year retrospective study from a single tertiary medical center

verfasst von: Yue Cao, Xin Chen, Qi Peng, Tian Tuo Huang, Xiao Chen Fan

Erschienen in: European Journal of Pediatrics | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Abstract

Immunoglobulin A vasculitis(IgAV) is the most common form of systemic vasculitis affecting children. To date, cardiac involvement in pediatric IgAV has not been fully investigated and its prevalence may be underestimated. This study aims to reveal the clinical and laboratory characteristics of cardiac involvement in pediatric IgAV and further determine its risk factors. A total of 1451 children with IgAV were recruited between January 2016 and December 2022. According to the severity of cardiac involvement, the patients were divided into the myocarditis/suspected myocarditis group, cardiac abnormalities group, and non-cardiac involvement group. Demographic, clinical, and laboratory characteristics were retrospectively extracted from the individual data collected in the medical records. Among the 1451 pediatric IgAV patients, 179 (12.3%) were identified with cardiac involvement, including 154 (10.6%) with cardiac abnormalities and 25 (1.7%) with myocarditis/suspected myocarditis. Cardiac involvement in pediatric IgAV mainly manifested as elevated cardiac biomarker levels (n = 162), electrocardiogram abnormalities (n = 46), and echocardiogram/chest X-ray abnormalities (n = 15); however, cardiac-related symptoms were only observed in 15.1% of patients with cardiac involvement. Multivariate analysis demonstrated that interval from disease onset to diagnosis > 7 days (OR, 2.157; 95% CI, 1.523–3.057; p < 0.001), IgAV with multi-organ involvement (OR, 1.806; 95% CI, 1.242–2.627; p = 0.002), and elevated D-dimer levels (OR, 1.939; 95% CI, 1.259–2.985; p < 0.001) were independent risk factors for cardiac involvement in pediatric IgAV. The length of hospital stay was significantly longer in the myocarditis/suspected myocarditis group compared with the other two groups (p < 0.05).
    Conclusion: This study suggests that cardiac involvements in pediatric IgAV is non-negligible, and cardiac involvement is associated with interval from disease onset to diagnosis > 7 days, IgAV with multi-organ involvement, and elevated D-dimer levels. Severe cardiac involvement may affect the prognosis of pediatric IgAV.
What is Known:
• Immunoglobulin A vasculitis (IgAV) is the most common form of systemic vasculitis affecting children and adolescents, which exhibits diverse clinical manifestations. Cases of severe IgAV complicated by cardiac involvement have been anecdotally reported.
What is New:
• The present study suggests that cardiac involvements in pediatric IgAV is non-negligible, and cardiac involvement is associated with interval from disease onset to diagnosis > 7 days, IgAV with multi-organ involvement, and elevated D-dimer levels. Severe cardiac involvement may affect the prognosis of pediatric IgAV.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
7.
Zurück zum Zitat Ozen S, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R et al (2010) EULAR, PRINTO, PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis (69):798–806. https://doi.org/10.1136/ard.2009.116657CrossRef Ozen S, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R et al (2010) EULAR, PRINTO, PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis (69):798–806. https://​doi.​org/​10.​1136/​ard.​2009.​116657CrossRef
9.
Zurück zum Zitat Subspecialty Group of Cardiology, the Society of Pediatrics, Chinese Medical Association; Collaborating Group of Myocarditis, the Subspecialty Group of Cardiology, the Society of Pediatrics, Chinese Medical Association; Editorial Board, Chinese Journal of Pediatrics; Pediatric Cardiology Committee, Chinese College of Cardiovascular Physicians, Chinese Medical Doctor Association (2019) Diagnostic recommendation for myocarditis in children (version 2018). Zhonghua Er Ke Za Zhi = Chin J Pediatr 57:87–89. https://doi.org/10.3760/cma.j.issn.0578-1310.2019.02.004 Subspecialty Group of Cardiology, the Society of Pediatrics, Chinese Medical Association; Collaborating Group of Myocarditis, the Subspecialty Group of Cardiology, the Society of Pediatrics, Chinese Medical Association; Editorial Board, Chinese Journal of Pediatrics; Pediatric Cardiology Committee, Chinese College of Cardiovascular Physicians, Chinese Medical Doctor Association (2019) Diagnostic recommendation for myocarditis in children (version 2018). Zhonghua Er Ke Za Zhi = Chin J Pediatr 57:87–89. https://​doi.​org/​10.​3760/​cma.​j.​issn.​0578-1310.​2019.​02.​004
14.
Zurück zum Zitat Ozen S, Marks SD, Brogan P, Groot N, de Graeff N, Avcin T, Bader-Meunier B, Dolezalova P, Feldman BM, Kone-Paut I, Lahdenne P, McCann L, Pilkington C, Ravelli A, van Royen A, Uziel Y, Vastert B, Wulffraat N, Kamphuis S, Beresford MW (2019) European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative. Rheumatology (Oxford) 58:1607–1616. https://doi.org/10.1093/rheumatology/kez041CrossRefPubMed Ozen S, Marks SD, Brogan P, Groot N, de Graeff N, Avcin T, Bader-Meunier B, Dolezalova P, Feldman BM, Kone-Paut I, Lahdenne P, McCann L, Pilkington C, Ravelli A, van Royen A, Uziel Y, Vastert B, Wulffraat N, Kamphuis S, Beresford MW (2019) European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative. Rheumatology (Oxford) 58:1607–1616. https://​doi.​org/​10.​1093/​rheumatology/​kez041CrossRefPubMed
15.
Zurück zum Zitat Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, Cook HT, Fervenza FC, Gibson KL, Glassock RJ, Jayne DRW, Jha V, Liew A, Liu ZH, Mejía-Vilet JM, Nester CM, Radhakrishnan J, Rave EM, Reich HN, Ronco P, Sanders JF, Sethi S, Suzuki Y, Tang SCW, Tesar V, Vivarelli M, Wetzels JFM, Lytvyn L, Craig JC, Tunnicliffe DJ, Howell M, Tonelli MA, Cheung M, Earley A, Floege J (2021) Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int 100:753–779. https://doi.org/10.1016/j.kint.2021.05.015CrossRefPubMed Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, Cook HT, Fervenza FC, Gibson KL, Glassock RJ, Jayne DRW, Jha V, Liew A, Liu ZH, Mejía-Vilet JM, Nester CM, Radhakrishnan J, Rave EM, Reich HN, Ronco P, Sanders JF, Sethi S, Suzuki Y, Tang SCW, Tesar V, Vivarelli M, Wetzels JFM, Lytvyn L, Craig JC, Tunnicliffe DJ, Howell M, Tonelli MA, Cheung M, Earley A, Floege J (2021) Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int 100:753–779. https://​doi.​org/​10.​1016/​j.​kint.​2021.​05.​015CrossRefPubMed
21.
25.
Zurück zum Zitat Sestan M, Kifer N, Sozeri B, Demir F, Ulu K, Silva CA, Campos RT, Batu ED, Koker O, Sapina M, Srsen S, Held M, Gagro A, Fonseca AR, Rodrigues M, Rigante D, Filocamo G, Baldo F, Heshin-Bekenstein M, Giani T, Kataja J, Frkovic M, Ruperto N, Ozen S, Jelusic M (2023) Vasculitis Working Party of the Pediatric Rheumatology European Society (PReS). Clinical features, treatment and outcome of pediatric patients with severe cutaneous manifestations in IgA vasculitis: multicenter international study. Semin Arthritis Rheum 61:152209. https://doi.org/10.1016/j.semarthrit.2023.152209CrossRefPubMed Sestan M, Kifer N, Sozeri B, Demir F, Ulu K, Silva CA, Campos RT, Batu ED, Koker O, Sapina M, Srsen S, Held M, Gagro A, Fonseca AR, Rodrigues M, Rigante D, Filocamo G, Baldo F, Heshin-Bekenstein M, Giani T, Kataja J, Frkovic M, Ruperto N, Ozen S, Jelusic M (2023) Vasculitis Working Party of the Pediatric Rheumatology European Society (PReS). Clinical features, treatment and outcome of pediatric patients with severe cutaneous manifestations in IgA vasculitis: multicenter international study. Semin Arthritis Rheum 61:152209. https://​doi.​org/​10.​1016/​j.​semarthrit.​2023.​152209CrossRefPubMed
Metadaten
Titel
Clinical characteristics and risk factors of cardiac involvement in pediatric immunoglobulin A vasculitis: A 7-year retrospective study from a single tertiary medical center
verfasst von
Yue Cao
Xin Chen
Qi Peng
Tian Tuo Huang
Xiao Chen Fan
Publikationsdatum
01.02.2024
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Pediatrics / Ausgabe 4/2024
Print ISSN: 0340-6199
Elektronische ISSN: 1432-1076
DOI
https://doi.org/10.1007/s00431-024-05438-1

Weitere Artikel der Ausgabe 4/2024

European Journal of Pediatrics 4/2024 Zur Ausgabe

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.